Elevation Oncology Acquires ADC Technology from Synaffix for Pipeline Growth

Synaffix B.V., a Lonza company, has entered into a strategic partnership with Elevation Oncology, Inc. to advance the development of a novel cancer treatment. This collaboration involves a licensing agreement allowing Elevation Oncology access to Synaffix's cutting-edge antibody-drug conjugate (ADC) technology. This partnership is aimed at developing a promising new HER3-targeting ADC candidate, EO-1022, that utilizes Synaffix’s advanced ADC technologies.

The agreement grants Elevation Oncology global rights to Synaffix's clinical-stage, site-specific ADC technology platform, which includes the GlycoConnect® antibody conjugation technology, HydraSpace® polar spacer technology, and the toxSYN® linker-payload platform. These technologies enable the creation of ADCs that potentially offer superior therapeutic potential. The collaboration underscores the strengths of Synaffix’s ADC technology, which transforms antibodies into differentiated ADCs with potentially enhanced safety and efficacy profiles.

Financially, the agreement could be substantial for Synaffix. The company is set to receive up to $368 million from Elevation Oncology, which includes upfront and milestone payments related to clinical, regulatory, and commercial targets, along with tiered royalties based on net sales. In this partnership, Synaffix will handle the manufacturing of its proprietary technology components, while Elevation Oncology will oversee the research, development, manufacturing, and commercialization aspects of the ADC.

Peter van de Sande, the Head of Synaffix, expressed enthusiasm about the collaboration, emphasizing the potential of Elevation Oncology to leverage their state-of-the-art ADC platform and established supply chain to advance the development of their HER3 ADC. He highlighted the collaboration as an essential step in pushing the boundaries of ADC innovation.

David Dornan, Elevation Oncology’s Chief Scientific Officer, shared similar excitement, noting that the partnership will allow them to develop a HER3 ADC candidate with the potential for best-in-class performance. This is a significant advancement towards their goal of transforming the treatment landscape for patients with solid tumors expressing HER3.

Synaffix is recognized for its proprietary platform that allows companies to develop their own ADC products using GlycoConnect®, HydraSpace®, and toxSYN® technologies. These innovations enable efficient development timelines and have garnered numerous partnerships with leading companies in the biotechnology sector.

Elevation Oncology is focused on creating targeted cancer therapies for solid tumors with high unmet needs. The company is building a pipeline based on ADC technology, initially targeting Claudin 18.2 and HER3. Their leading candidate, EO-3021, is undergoing a Phase 1 trial for treating tumors likely to express Claudin 18.2. The newly nominated EO-1022, focusing on HER3, is currently in preclinical development and represents a critical component of their strategy to address pressing oncological challenges.

This partnership between Synaffix and Elevation Oncology exemplifies the potential of combining innovative technology platforms with focused therapeutic objectives to develop new, effective treatments for cancer. Through this collaboration, both companies aim to make significant strides in the field of oncology, providing new hope for patients with challenging tumor profiles.